A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical ...
When Heather Guidone learned she had endometriosis in the 1980s, she had never heard of it. “The doctor said, ‘Well, the good news is we have a diagnosis. The bad news is you’re probably not going to ...
Excision BioTherapeutics has licensed recently discovered CRISPR gene editors from UC Berkeley. The deal gives Excision the exclusive right to use the Cas9 alternatives to treat infectious diseases.
Excision has announced a new tour, "Nexus Tour," which is scheduled to take place from December 22, 2023, to June 22, 2024, in venues across the mainland United States and Canada. The tour will be the ...
SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results